Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.

Hunsucker, Sally A

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. [electronic resource] - British journal of haematology Mar 2011 - 579-92 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1365-2141

10.1111/j.1365-2141.2010.08533.x doi


Antibodies, Monoclonal--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Apoptosis--drug effects
BH3 Interacting Domain Death Agonist Protein--metabolism
Cell Survival--drug effects
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Humans
Interleukin-6--antagonists & inhibitors
Melphalan--administration & dosage
Multiple Myeloma--metabolism
Neoplasm Proteins--metabolism
Plasma Cells--drug effects
Proto-Oncogene Proteins c-akt--metabolism
Signal Transduction--drug effects
Tumor Cells, Cultured
bcl-2 Homologous Antagonist-Killer Protein--metabolism
bcl-2-Associated X Protein--metabolism